Regardless of the mechanism of action, our current results demonstrate that postprandial hyperinsulinemia may be reduced using a synthetic GLP-1 agonist and this may be useful for the therapy of insulin dysregulation in horses with ID. This evidence concerns the gene INS and Hyperinsulinemia.